Guidance maintained amid transition to newer growth avenues
29/10/26 -"The Q3 EBITDA was somewhat ahead of expectations, unlike sales. While lower demand in Spain and loss of exclusivity in Japan impaired Bilastine’s sales, the addition of Ophthalmology (with 2025 ..."
Pages
45
Language
English
Published on
29/10/26
You may also be interested by these reports :
06/11/26
Genmab’s sales missed expectations, but profitability significantly exceeded expectations. Growth was driven by contributions from most offerings, ...
06/11/26
Sanofi’s growth in recent years has been single-handedly driven by its cornerstone immunology treatment Dupixent, though there has been some support ...
06/11/26
Novonesis delivered an in-line Q3 26, with revenue and adjusted EBITDA marginally ahead of consensus. Food & Beverages (F&B) accelerated to 14%, ...
05/11/26
The Q3 qualitative update did not materially change the full-year outlook, as Branded’s strong momentum made up for the relative weakness in ...